Duo Oncology to Present Breakthrough DUO-207 Research at 2025 ASCO GI Conference.
Dr. Katherine Eichinger, will present data from DUO-207’s IND-enabling studies at the prestigious 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
PITTSBURGH (PRWEB) January 7, 2025 – Duo Oncology, a leader in innovative nanomedicine, is thrilled to announce that its COO, Dr. Katherine Eichinger, will present groundbreaking research on its flagship product, DUO-207, at the prestigious 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).
The presentation, titled “Toxicology and Clinical Protocol Development of DUO-207: An Ultrasmall Nanomedicine Co-Delivering Gemcitabine and Paclitaxel for the Treatment of Metastatic Pancreatic Cancer,” will detail preclinical toxicology results and the design of a forthcoming Phase 1 clinical trial.
DUO-207 is a groundbreaking, ultrasmall nanomedicine (~20 nm) that co-delivers two foundational therapies in a single intravenous infusion. Its unique size and chemistry allow it to achieve greater tumor penetration compared to traditional nanomedicines. Preclinical GLP toxicology studies in canines demonstrated strong safety signals, including recoverable hematologic toxicities without signs of renal or hepatic toxicity. Results from a rat efficacy study showed that DUO-207 had significantly less toxicity and greater intratumoral drug concentrations of gemcitabine (GEM) and paclitaxel (PTX) than standard of care (GEM + nAb-PTX) dosing in a pancreatic cancer model. These findings informed the design of a robust Phase I clinical trial using the continual reassessment method to optimize dose escalation.
“We’re incredibly excited to share our findings at ASCO GI 2025,” said Dr. Sam Rothstein, CEO of Duo Oncology. “DUO-207 represents a significant advancement in addressing the challenges of treating metastatic pancreatic cancer. Our research underscores the potential of advanced nanomedicine chemistry to revolutionize the foundation of cancer therapy.”
Presentation Details:
· Session Title: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
· Presenter: Katherine Eichinger, COO
· Date: 11:30 am – 1pm on January 24, 2025
· Location: Moscone West, 800 Howard Street, San Francisco, CA 94103
For more information about Duo Oncology and its mission to revolutionize cancer treatment, please visit DuoOncology.com.
